Apixaban for Prevention of Blood Clots in Children With Leukemia
Full IRB Study Title:
A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Pegylated (PEG) L-Asparaginase
IRB Study ID: 150408
The purpose of this study is to compare the effect of a blood thinning drug called Apixaban versus no administration of a blood thinning drug, in preventing blood clots in children with leukemia or lymphoma. Patients must be receiving chemotherapy; including Pegylated L-Asparaginase and have a central line (a catheter inserted for administration of medications and blood sampling).
Complete study information: https://clinicaltrials.gov/ct2/show/NCT02369653
Study Sponsor:
Bristol Myers - Squibb
Who May Qualify:
- Patients with a new diagnosis of de novo ALL, lymphomas (T or B cell), or mixed-phenotype acute leukemia
- Patients with a functioning Central Venous Access Device ( i.v. bag used to administer drugs through the vein)
- Patients who are able to tolerate oral medication or have it administered via an Nasogastric tube (NGT) or GT tube
- Males and females, age 1 year (365 days) to < 18 (17 years and 364 days) years.
- Patients with platelet Counts ≥ 20000/microL
Who Does NOT Qualify:
Patients:
- Scheduled to have > 3 Lumbar Punctures over the course of the treatment period ( often known to the public as “spinals”)
- With prior history of documented DVT or PE in the past 3 months
- With known inherited bleeding disorder or clotting disorder.
- Who have had major surgery [excluding Central Venous Access Device (CVAD) replacement and bone marrow aspiration and non-open biopsy] within the last 7 days prior to enrollment that may be associated with a risk of bleeding. Open biopsy is considered a major surgery.
- With uncontrolled severe hypertension at enrollment (high blood pressure). Severe hypertension is defined as a systolic or diastolic blood pressure (BP) > 5 mm Hg above the 95th percentile as defined by the National High Blood Pressure Education Program Working Group (NHBPEP) established guidelines for the definition of normal and elevated blood pressure in children
- With extreme hyper leukocytosis, white blood cell (WBC) counts over 200 x 109/L (200,000/microL) at the time of enrollment
- With liver disease or liver dysfunction.
- With history of significant adverse reaction or major bleeding related adverse reaction to other anticoagulant or antiplatelet agents
- With history of any significant drug allergy. Any investigational drug being administered during the study